National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting, 45225 [E9-20862]
Download as PDF
Federal Register / Vol. 74, No. 168 / Tuesday, September 1, 2009 / Notices
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Child Health and Human Development
Council.
Date: September 21, 2009.
Open: 8 a.m. to 12:30 p.m.
Agenda: (1) A report by the Director,
NICHD; (2) and annual review of the Division
of Intramural Research; (3) Intellectual and
Developmental Disabilities Branch
Presentation; and other business of the
Council.
Place: National Institutes of Health,
Building 31, 31 Center Drive, C–Wing,
Conference Room 6, Bethesda, MD 20892.
Closed: 1:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Building 31, 31 Center Drive, C–Wing,
Conference Room 6, Bethesda, MD 20892.
Contact Person: Yvonne T. Maddox, PhD,
Deputy Director, National Institute of Child
Health, and Human Development, NIH, 9000
Rockville Pike MSC 7510, Building 31, Room
2A03, Bethesda, MD 20892, (301) 496–1848.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nichd.nih.gov/about/nachhd.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
mstockstill on DSKH9S0YB1PROD with NOTICES
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: August 25, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–21045 Filed 8–31–09; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Food and Drug Administration
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meeting
[Docket No. FDA–2009–E–0058]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism, Initial
Review Group; Clinical, Treatment and
Health Services Research Review
Subcommittee.
Date: October 13–14, 2009.
Time: 8:30 a.m to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites Hotel at the Chevy
Chase Pavilion, 4300 Military Road, NW.,
Washington, DC.
Contact Person: Katrina L. Foster, PhD,
Scientific Review Officer, National Institute
on Alcohol Abuse & Alcoholism, National
Institutes of Health, 5635 Fishers Lane, Rm.
2019, Rockville, MD 20852. 301–443–4032,
katrina@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards, National
Institutes of Health, HHS).
Dated: August 24, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–20862 Filed 8–31–09; 8:45 am]
BILLING CODE 4140–01–M
BILLING CODE 4140–01–P
VerDate Nov<24>2008
17:18 Aug 31, 2009
Jkt 217001
45225
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
Determination of Regulatory Review
Period for Purposes of Patent
Extension; TAPENTADOL
HYDROCHLORIDE
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) has determined
the regulatory review period for
TAPENTADOL HYDROCHLORIDE and
is publishing this notice of that
determination as required by law. FDA
has made the determination because of
the submission of an application to the
Director of Patents and Trademarks,
Department of Commerce, for the
extension of a patent which claims that
human drug product.
ADDRESSES: Submit written comments
and petitions to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 51,
rm. 6222, Silver Spring, MD 20993–
0002, 301–796–3602.
SUPPLEMENTARY INFORMATION: The Drug
Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98–
417) and the Generic Animal Drug and
Patent Term Restoration Act (Public
Law 100–670) generally provide that a
patent may be extended for a period of
up to 5 years so long as the patented
item (human drug product, animal drug
product, medical device, food additive,
or color additive) was subject to
regulatory review by FDA before the
item was marketed. Under these acts, a
product’s regulatory review period
forms the basis for determining the
amount of extension an applicant may
receive.
A regulatory review period consists of
two periods of time: A testing phase and
an approval phase. For human drug
products, the testing phase begins when
the exemption to permit the clinical
investigations of the drug becomes
effective and runs until the approval
phase begins. The approval phase starts
with the initial submission of an
application to market the human drug
product and continues until FDA grants
E:\FR\FM\01SEN1.SGM
01SEN1
Agencies
[Federal Register Volume 74, Number 168 (Tuesday, September 1, 2009)]
[Notices]
[Page 45225]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-20862]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse and Alcoholism; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Alcohol Abuse and
Alcoholism, Initial Review Group; Clinical, Treatment and Health
Services Research Review Subcommittee.
Date: October 13-14, 2009.
Time: 8:30 a.m to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites Hotel at the Chevy Chase Pavilion, 4300
Military Road, NW., Washington, DC.
Contact Person: Katrina L. Foster, PhD, Scientific Review
Officer, National Institute on Alcohol Abuse & Alcoholism, National
Institutes of Health, 5635 Fishers Lane, Rm. 2019, Rockville, MD
20852. 301-443-4032, katrina@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.271,
Alcohol Research Career Development Awards for Scientists and
Clinicians; 93.272, Alcohol National Research Service Awards for
Research Training; 93.273, Alcohol Research Programs; 93.891,
Alcohol Research Center Grants; 93.701, ARRA Related Biomedical
Research and Research Support Awards, National Institutes of Health,
HHS).
Dated: August 24, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-20862 Filed 8-31-09; 8:45 am]
BILLING CODE 4140-01-M